Verge Genomics rebranded as Verge Labs after reporting failure in an early clinical trial of VRG50635, an AI-designed experimental drug for ALS. The company said it laid off about 90% of staff as part of the pivot and is now positioning itself as a data provider for drug developers instead of a drug trial operator. The earlier program was built around inhibiting PIKfyve based on AI-discovery rationale, with neurofilament light chain measured to assess nerve damage; the trial reportedly found increased levels, undermining the expected on-target direction of effect. Verge said it will feed learnings back into its platform and that dataset monetization will underpin its future model. For the sector, the key implication is that AI drug discovery economics are tightening: when translational targets miss, companies may pivot toward enabling tools and target/biomarker data packages rather than taking full clinical risk themselves. Watch items include Verge Labs’ partnership strategy, customer adoption for its datasets, and whether it can convert prior trial readouts into stronger target selection and biomarker models.